Description:RecombinantmonoclonalantibodytoEnvelopeproteinDIII.ManufacturedusingAbAb’sRecombinantPlatformwithvariableregions(i.e.specificity)fromthehybridoma2D73.ThisantibodywascreatedusingourproprietaryFcSilent™engineeredFcdomaincontainingkeypointmutationsthatabrogatebindingtoFcgammareceptors.
ThischimerichumanantibodywasmadeusingthevariabledomainsequencesoftheoriginalMouseIgG1format,forimprovedcompatibilitywithexistingreagents,assaysandtechniques.
SpeciesandIsotype:HumanIgG1,FcSilent™,kappa
CloneNumber:2D73
UniProtAccessionNumberofTargetProtein:PublishedApplication(s):ELISA;crystallisation
PublishedSpeciesReactivity:DENV
Immunogen:BALB/cmicewereimmunisedwithrecombinantly-producedenvelopeproteindomainIII(EDIII)fromDENV-3.SplenocyteswereobtainedfromimmunisedmiceandfusedwiththeNS-1myelomacelllinetogeneratehybridomas.
Specificity:2D73reactswithresidues309-319(DKEMAETQHGT)withindomainIIIoftheDENVenvelopeprotein,showncrystallographically(Lietal,unpublished).AlthoughraisedagainstDENV-3EDIII,2D72cross-reactswithEDIIIfromallfourDENV
SEROtypes.2D73doesnotreactwithotherDENV-relatedflaviviruses,suchasWNV,YFVandJEV.
ApplicationNotes:2D73wasabletostronglyneutraliseDENVinfectioninaserotype-independentmanner,shownusingbothELISAsandELISPOT-basedassays(Lietal,2013).2D73hasalsobeenused,asaFabfragment,tocrystallisetheDENV-4EDIIIprotein(Lietal,unpublished).
AntibodyFirstPublishedin:Lietal.DenguevirusenvelopedomainIIIimmunizationelicitspredominantlycross-reactive,poorlyneutralizingantibodieslocalizedtotheABloop:implicationsfordenguevaccinedesign.JGenVirol.2013Oct;94(Pt10):2191-201.PMID:23851440
Noteonpublication:Describesthegenerationandcharacterisationof25cross-reactiveanti-DENVmAbs.
ProductForm
Purification:ProteinAaffinitypurified
Suppliedin:PBSwith0.02%Proclin300.
StorageRecommendation:Storeat4°Cforupto3months.Forlongertermstoragealiquotintosmallvolumesandstoreat-20°C
Concentration:Seeviallabel.
Importantnote–Thisproductisforresearchuseonly.Itisnotintendedforuseintherapeuticordiagnosticproceduresforhumansoranimals.